The Food and Drug Administration has granted Fast Track designation to SAR402663 for the treatment of neovascular AMD.

At least 20 million Americans ages 40 and older have age-related macular degeneration, and the threat posed by the vision-robbing condition will only grow larger as the population ages. Despite the ...

The amplitude of retinal thickness fluctuations in the early months of anti-VEGF treatment have no effect on later functional outcomes.

SOL-1 superiority trial continues to demonstrate outstanding patient retention and protocol adherence, with no new or unexpected safety signals ...

D Molecular Therapeutics (FDMT) offers attractive growth potential with strong cash reserves and promising late-stage gene ...

In a new study, Picture Health's QVT score identified responders and non-responders to immunotherapy and chemoimmunotherapy.

CStone Pharmaceuticals ( ($HK:2616) ) has provided an update. CStone Pharmaceuticals announced the enrollment of the first patient in Australia ...

Akeso Inc. (9926.HK) has announced that the first patient has been dosed in its registrational Phase II study (AK130-202), ...

Kalaris Therapeutics initiates a phase 1b/2 study for TH103, targeting neovascular age-related macular degeneration and ...

The therapy is expected to block abnormal blood vessel growth, limit vascular leakage, and reduce retina damage. The Food and Drug Administration (FDA) has granted Fast Track designation to SAR402663 ...

Anti-vascular endothelial growth factor (anti-VEGF) agents have demonstrated efficacy and short-term safety in the treatment of retinopathy of prematurity (ROP), establishing them as the preferred ...

Department of Ophthalmology, National Taiwan University Hospital, Hsinchu Branch, Hsinchu 302, Taiwan Department of Ophthalmology, National Taiwan University Hospital, Taipei 100, Taiwan Graduate ...